These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 33998168)

  • 1. Subretinal fluid morphology in chronic central serous chorioretinopathy and its relationship to treatment: a retrospective analysis on PLACE trial data.
    Subhi Y; Bjerager J; Boon CJF; van Dijk EHC
    Acta Ophthalmol; 2022 Feb; 100(1):89-95. PubMed ID: 33998168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser.
    van Rijssen TJ; van Dijk EHC; Scholz P; Breukink MB; Dijkman G; Peters PJH; Tsonaka R; Keunen JEE; MacLaren RE; Hoyng CB; Downes SM; Fauser S; Boon CJF
    Acta Ophthalmol; 2021 Nov; 99(7):805-811. PubMed ID: 33565230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focal and Diffuse Chronic Central Serous Chorioretinopathy Treated With Half-Dose Photodynamic Therapy or Subthreshold Micropulse Laser: PLACE Trial Report No. 3.
    van Rijssen TJ; van Dijk EHC; Scholz P; Breukink MB; Blanco-Garavito R; Souied EH; Keunen JEE; MacLaren RE; Querques G; Fauser S; Downes SM; Hoyng CB; Boon CJF
    Am J Ophthalmol; 2019 Sep; 205():1-10. PubMed ID: 30951686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea.
    van Dijk EHC; Dijkman G; Boon CJF
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2029-2035. PubMed ID: 28674835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous Chorioretinopathy: The PLACE Trial.
    van Dijk EHC; Fauser S; Breukink MB; Blanco-Garavito R; Groenewoud JMM; Keunen JEE; Peters PJH; Dijkman G; Souied EH; MacLaren RE; Querques G; Downes SM; Hoyng CB; Boon CJF
    Ophthalmology; 2018 Oct; 125(10):1547-1555. PubMed ID: 29776672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crossover to Photodynamic Therapy or Micropulse Laser After Failure of Primary Treatment of Chronic Central Serous Chorioretinopathy: The REPLACE Trial.
    van Rijssen TJ; van Dijk EHC; Scholz P; Breukink MB; Dijkman G; Peters PJH; Tsonaka R; MacLaren RE; Downes SM; Fauser S; Boon CJF; Hoyng CB
    Am J Ophthalmol; 2020 Aug; 216():80-89. PubMed ID: 32289294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol.
    Breukink MB; Mohr JK; Ossewaarde-van Norel A; den Hollander AI; Keunen JE; Hoyng CB; Boon CJ
    Acta Ophthalmol; 2016 Mar; 94(2):187-97. PubMed ID: 26670630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing Half-Dose Photodynamic Therapy with Subthreshold Micropulse Laser for the Treatment of Central Serous Chorioretinopathy.
    Brelen ME; Ho M; Li S; Ng DSC; Yip YWY; Lee WS; Chen LJ; Young AL; Tham CC; Pang CP
    Ophthalmol Retina; 2024 May; 8(5):490-498. PubMed ID: 37956794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY-GUIDED PHOTODYNAMIC THERAPY FOR ACUTE CENTRAL SEROUS CHORIORETINOPATHY.
    Hu J; Qu J; Li M; Sun G; Piao Z; Liang Z; Yao Y; Sadda S; Zhao M
    Retina; 2021 Jan; 41(1):189-198. PubMed ID: 32343102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy.
    van Rijssen TJ; van Dijk EHC; Dijkman G; Boon CJF
    Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1395-1402. PubMed ID: 29732468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crossover to Half-Dose Photodynamic Therapy or Eplerenone in Chronic Central Serous Chorioretinopathy Patients.
    Feenstra HMA; van Dijk EHC; van Rijssen TJ; Tsonaka R; Diederen RMH; Schlingemann RO; Hoyng CB; Boon CJF
    Ophthalmol Retina; 2022 Oct; 6(10):930-938. PubMed ID: 35470085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional and anatomical results of subthreshold micropulse laser as rescue treatment for central serous chorioretinopathy after verteporfin shortage.
    Oribio-Quinto C; Alarcón-Garcia AD; Enriquez-Fuentes J; Burgos-Blasco B; Fernandez-Vigo JI
    Photodiagnosis Photodyn Ther; 2024 Oct; 49():104295. PubMed ID: 39067672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fuji sign: Prevalence and predictive power to photodynamic therapy in chronic central serous chorioretinopathy.
    Pérez-García P; Oribio-Quinto C; Gómez-Calleja V; Moreno-Morillo FJ; Burgos-Blasco B; Fernández-Vigo JI
    Photodiagnosis Photodyn Ther; 2023 Jun; 42():103316. PubMed ID: 36746235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective evaluation of changes in choroidal vascularity index after half-dose photodynamic therapy versus micropulse laser treatment in chronic central serous chorioretinopathy.
    van Rijssen TJ; Singh SR; van Dijk EHC; Rasheed MA; Vupparaboina KK; Boon CJF; Chhablani J
    Graefes Arch Clin Exp Ophthalmol; 2020 Jun; 258(6):1191-1197. PubMed ID: 32170365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Retinochoroidal Vascular and Structural Changes after Half-Dose Photodynamic Therapy versus Half-Fluence Photodynamic Therapy Based on Optical Coherence Tomography Angiography in Eyes with Chronic Central Serous Chorioretinopathy.
    Karasu B; Akbas YB; Aykut A; Celebi ARC
    Ophthalmologica; 2022; 245(4):323-334. PubMed ID: 35249031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors of persistent subretinal fluid after half-dose photodynamic therapy for treatment-naïve central serous chorioretinopathy.
    Li M; Qu J; Liang Z; Tang J; Hu J; Yao Y; Jin E; Li X; Zhao M
    Graefes Arch Clin Exp Ophthalmol; 2022 Jul; 260(7):2175-2182. PubMed ID: 35024912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Outcomes of Full-Fluence and Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
    Son BK; Kim K; Kim ES; Yu SY
    Ophthalmologica; 2019; 241(2):105-115. PubMed ID: 30110697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. INSTRUMENTAL DIFFERENCE IN ASSESSING CHOROIDAL HYPERPERMEABILITY AND PHOTODYNAMIC THERAPY IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Lee SM; Kwon HJ; Park SW; Lee JE; Byon IS
    Retina; 2019 Jul; 39(7):1361-1369. PubMed ID: 29554076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Half-dose photodynamic therapy versus 577 nm subthreshold pulse laser therapy in treatment-naive patients with central serous chorioretinopathy.
    Sitnilska V; Schiller P; Krohne TU; Altay L
    BMC Ophthalmol; 2024 Jan; 24(1):8. PubMed ID: 38178104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of half-dose versus half-fluence versus standard photodynamic therapy in chronic central serous chorioretinopathy.
    Altinel MG; Kanra AY; Totuk OMG; Ardagil A; Kabadayi K
    Photodiagnosis Photodyn Ther; 2021 Mar; 33():102081. PubMed ID: 33157327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.